Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.
about
Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatmentTargets for therapy in sarcomeric cardiomyopathiesOrthostatic blood pressure test for risk stratification in patients with hypertrophic cardiomyopathy.Impact of detubulation on force and kinetics of cardiac muscle contraction.How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience.Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability.Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.Relationship between Regional Fat Distribution and Hypertrophic Cardiomyopathy PhenotypeHypertrophic cardiomyopathy: The need for randomized trialsDefining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association.Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of EchocPharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy.The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities.Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease.Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.Current state of the art and future of myectomy.Life-long tailoring of management for patients with hypertrophic cardiomyopathy : Awareness and decision-making in changing scenarios.Cardiomyocyte-Specific Telomere Shortening is a Distinct Signature of Heart Failure in Humans.Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy.Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study.Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.Short-term beat-to-beat variability of the QT interval is increased and correlates with parameters of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy.Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathyFollow-up and prognosis of HCMAltered Ca and Na Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis
P2860
Q26863221-45E07854-CF15-42A9-8C4C-66A2505E30ACQ27027023-CE021C2B-7396-4069-9A86-F1DAFDE8149DQ33165901-E3C40295-3ABC-4515-91A5-481B937F3C7BQ33672949-3B585298-3646-41E2-A4A8-6B3E4518AF7BQ33795944-624607BE-3B06-42F1-BEB7-CE142606609EQ34428462-1F57838F-C472-4DCF-8D24-7B9F9A911D27Q34732430-2FB8CE65-EA08-4CC6-B1B3-7F73D4F272B9Q36070076-5949D6D5-F755-4E61-85B2-64F3B4DC4D9FQ37659240-FC3A20FB-57AC-481F-BE04-C0BA1204DE7DQ38336102-B48EE902-7FDC-4A82-BED7-E462D5B75135Q38343713-457C2C40-8D8E-4820-A106-7640FC2C4CC6Q38782767-A92B00C3-B585-4473-A525-CA4DBA907E44Q38816364-64522934-FDEE-441A-A4C0-3AC841766A74Q38875297-BE8E4EBB-3A48-423F-B0AD-18AF354D7D12Q38978665-3372515B-CA7B-4D48-9DA8-5568AAE0622EQ39004331-8939B7B6-2FCD-4B4F-8A5F-F1D88617ABBBQ40492999-D775712B-9B27-4CA7-B2DA-3480673FFFD0Q41627235-AD94B381-399E-4173-B6A6-5135E50771E5Q41698069-8E0C2320-02FD-4416-A511-D0042748FE69Q42320941-7B084680-E77F-4576-A9DD-B2B85E55DB23Q42373663-2E9EEF51-F9F6-4ADE-A984-87B882A88BDFQ49882490-A29334B0-748B-4A4A-920E-895DD7398E53Q51718004-0F567144-26D5-4A8C-A89C-AB1F4552C180Q53270121-2A8917B4-7E88-4B66-BD20-B2B2320EB586Q53365475-B668BBB1-BA96-4166-9C4E-43183F144F72Q57988200-9632DE7C-9C0D-4191-B4C9-3E04309B9569Q58565523-57D179FD-AEFB-495F-9D87-8B9122D83330Q58699044-2EEDE408-5E4F-4014-A7C7-B9AAC4E8EDBA
P2860
Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Patterns of disease progressio ...... approach to clinical staging.
@en
type
label
Patterns of disease progressio ...... approach to clinical staging.
@en
prefLabel
Patterns of disease progressio ...... approach to clinical staging.
@en
P2093
P1476
Patterns of disease progressio ...... approach to clinical staging.
@en
P2093
Corrado Poggesi
Iacopo Olivotto
Magdi H Yacoub
P304
P356
10.1161/CIRCHEARTFAILURE.112.967026
P577
2012-07-01T00:00:00Z